🔗 Share this article

While the United States proceeds with historic changes to its vaccine guidelines, an unexpected name has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her short tenure at the FDA.

Proposed Changes to Childhood Vaccine Schedule

Public health authorities had intended to unveil major revisions to the pediatric vaccine schedule in December, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of step with much of the international standard with no evidence for public health gain. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Høeg is listed to speak at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with universal health coverage and a population about the population of Wisconsin’s.

So far comments, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

Høeg has little discernible background in drug development, oversight or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Former directors of CBER would “grasp laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that former directors who ran the center have had.”

This division has an vast range of responsibilities at the agency, Woodcock emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those need to be supervised,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant administrative component to the role, which supervises in excess of 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” she added.

Official Statement and Contentious Programs

Regarding questions about Høeg’s qualifications and whether this assignment represents more teamwork among agency officials on immunizations, a representative said that the “concerns are based on inaccurate assumptions”.

“This background is consistent with the functions of her job,” the representative stated, citing the period Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that reportedly concerned her predecessors. “By what process are these medications being chosen for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed oversight of most medications, with the exception of immunizations.”

Public Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, past, Howard observe. She released a analysis using unconfirmed public submissions to assess the rate of myocarditis after COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the current administration included altering regulations for novel immunizations and halting “non-essential” vaccines, she said post-election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of barring young men from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her preconceived notions and works backwards to fit the science in a very deceptive, dishonest manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|